LOGIN  |  REGISTER
Cue Biopharma

Ardent Health Announces Third Quarter 2025 Results Conference Call and Webcast Date

October 22, 2025 | Last Trade: US$8.96 0.34 -3.66

BRENTWOOD, Tenn. / Oct 22, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its third quarter 2025 results after the market closes on Wednesday, November 12, 2025. A conference call will be held the following day, Thursday, November 13, 2025, at 9 a.m. ET to review the Company’s financial results and conduct a question-and-answer session.

A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent’s website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download, and install any necessary audio software.

To participate in the live teleconference:

North America Toll-Free:

 

1-888-596-4144

International Toll:

 

1-646-968-2525

Access Code:

 

4437657

To listen to a replay of the teleconference, which will be available through November 27, 2025:

North America Toll-Free:

 

1-800-770-2030

International Toll:

 

1-647-362-9199

Access Code:

 

4437657

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 employed and affiliated providers across six states. For more information, please visit ardenthealth.com.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page